603 related articles for article (PubMed ID: 30306365)
21. Delivery of CRISPR/Cas9 for therapeutic genome editing.
Xu X; Wan T; Xin H; Li D; Pan H; Wu J; Ping Y
J Gene Med; 2019 Jul; 21(7):e3107. PubMed ID: 31237055
[TBL] [Abstract][Full Text] [Related]
22. Non-viral delivery of genome-editing nucleases for gene therapy.
Wang M; Glass ZA; Xu Q
Gene Ther; 2017 Mar; 24(3):144-150. PubMed ID: 27797355
[TBL] [Abstract][Full Text] [Related]
23. Cell-Selective Messenger RNA Delivery and CRISPR/Cas9 Genome Editing by Modulating the Interface of Phenylboronic Acid-Derived Lipid Nanoparticles and Cellular Surface Sialic Acid.
Tang Q; Liu J; Jiang Y; Zhang M; Mao L; Wang M
ACS Appl Mater Interfaces; 2019 Dec; 11(50):46585-46590. PubMed ID: 31763806
[TBL] [Abstract][Full Text] [Related]
24. Direct Cytosolic Delivery of CRISPR/Cas9-Ribonucleoprotein for Efficient Gene Editing.
Mout R; Ray M; Yesilbag Tonga G; Lee YW; Tay T; Sasaki K; Rotello VM
ACS Nano; 2017 Mar; 11(3):2452-2458. PubMed ID: 28129503
[TBL] [Abstract][Full Text] [Related]
25. A CRISPR/Cas9 based polymeric nanoparticles to treat/inhibit microbial infections.
Verma R; Sahu R; Singh DD; Egbo TE
Semin Cell Dev Biol; 2019 Dec; 96():44-52. PubMed ID: 30986568
[TBL] [Abstract][Full Text] [Related]
26. Current advances in overcoming obstacles of CRISPR/Cas9 off-target genome editing.
Aquino-Jarquin G
Mol Genet Metab; 2021; 134(1-2):77-86. PubMed ID: 34391646
[TBL] [Abstract][Full Text] [Related]
27. Spatiotemporal Delivery of CRISPR/Cas9 Genome Editing Machinery Using Stimuli-Responsive Vehicles.
Cai W; Luo T; Mao L; Wang M
Angew Chem Int Ed Engl; 2021 Apr; 60(16):8596-8606. PubMed ID: 32385892
[TBL] [Abstract][Full Text] [Related]
28. Delivery of CRISPR/Cas9 by Novel Strategies for Gene Therapy.
Wang L; Zheng W; Liu S; Li B; Jiang X
Chembiochem; 2019 Mar; 20(5):634-643. PubMed ID: 30393919
[TBL] [Abstract][Full Text] [Related]
29. Key considerations in designing CRISPR/Cas9-carrying nanoparticles for therapeutic genome editing.
Xu Y; Liu R; Dai Z
Nanoscale; 2020 Oct; 12(41):21001-21014. PubMed ID: 33078813
[TBL] [Abstract][Full Text] [Related]
30. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
[TBL] [Abstract][Full Text] [Related]
31. A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing.
Finn JD; Smith AR; Patel MC; Shaw L; Youniss MR; van Heteren J; Dirstine T; Ciullo C; Lescarbeau R; Seitzer J; Shah RR; Shah A; Ling D; Growe J; Pink M; Rohde E; Wood KM; Salomon WE; Harrington WF; Dombrowski C; Strapps WR; Chang Y; Morrissey DV
Cell Rep; 2018 Feb; 22(9):2227-2235. PubMed ID: 29490262
[TBL] [Abstract][Full Text] [Related]
32. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
[TBL] [Abstract][Full Text] [Related]
33. A Guanidinobenzol-Rich Polymer Overcoming Cascade Delivery Barriers for CRISPR-Cas9 Genome Editing.
Liang S; Ma N; Li X; Yun K; Meng QF; Ma K; Yue L; Rao L; Chen X; Wang Z
Nano Lett; 2024 Jun; 24(23):6872-6880. PubMed ID: 38683656
[TBL] [Abstract][Full Text] [Related]
34. Latest progress in the study of nanoparticle-based delivery of the CRISPR/Cas9 system.
Yu M; Liu X; Cheng H; Kuang L; Zhang S; Yan X
Methods; 2021 Oct; 194():48-55. PubMed ID: 34107351
[TBL] [Abstract][Full Text] [Related]
35. Revolutionizing Lung Cancer Treatment: Innovative CRISPR-Cas9 Delivery Strategies.
Singh D
AAPS PharmSciTech; 2024 Jun; 25(5):129. PubMed ID: 38844700
[TBL] [Abstract][Full Text] [Related]
36. Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications.
Liu C; Zhang L; Liu H; Cheng K
J Control Release; 2017 Nov; 266():17-26. PubMed ID: 28911805
[TBL] [Abstract][Full Text] [Related]
37. [Application of nanoparticles in CRISPR/Cas9-based gene therapy].
Ma Y; Deng L; Li S
Sheng Wu Gong Cheng Xue Bao; 2022 Jun; 38(6):2087-2104. PubMed ID: 35786464
[TBL] [Abstract][Full Text] [Related]
38. CRISPR/Cas9 delivery by NIR-responsive biomimetic nanoparticles for targeted HBV therapy.
Wang D; Chen L; Li C; Long Q; Yang Q; Huang A; Tang H
J Nanobiotechnology; 2022 Jan; 20(1):27. PubMed ID: 34991617
[TBL] [Abstract][Full Text] [Related]
39. Recent Advances in CRISPR/Cas9 Delivery Strategies.
Yip BH
Biomolecules; 2020 May; 10(6):. PubMed ID: 32486234
[TBL] [Abstract][Full Text] [Related]
40. Cationic Polymer-Mediated CRISPR/Cas9 Plasmid Delivery for Genome Editing.
Zhang Z; Wan T; Chen Y; Chen Y; Sun H; Cao T; Songyang Z; Tang G; Wu C; Ping Y; Xu FJ; Huang J
Macromol Rapid Commun; 2019 Mar; 40(5):e1800068. PubMed ID: 29708298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]